IMPORTANT Neurotrope, Inc. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Neurotrope, Inc. 

NEW YORK, May 19, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a class action lawsuit has been filed against Neurotrope, Inc. ("Neurotrope" or the "Company") (NASDAQ:NTRP) in the United States District Court for the Southern District of New York on behalf of shareholders who purchased Neurotrope securities between January 7, 2016, and April 28, 2017, both dates inclusive (the "Class Period").

Investors who have incurred losses in shares of Neurotrope, Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If you suffered a loss in Neurotrope, Inc. and would like to assist with the litigation process as a lead plaintiff, you may, no later than July 17, 2017, request that the Court appoint you lead plaintiff of the proposed class.

The filed Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding the efficacy of its lead product candidate, Bryostatin-1.

On May 1, 2017, Neurotrope announced "positive top-line results" of the focal Phase 2b trials of Bryostatin-1, mentioning "improvement in patients with moderate to severe Alzheimer's disease," The trial data allegedly negates these statements, as the top-line data relating to the 20 microgram dose of Bryostatin-1 did not produce statistically significant results. Neurotrope also allegedly failed to disclose statements about the efficacy of the 40 microgram dose in connection with its primary and secondary endpoints.

Following this news, Neurotrope stock dropped from a close of $18.81 per share on April 28, 2017, to close at $6.97 per share on May 1, 2017, the subsequent trading day.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP 
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.